

PATENT APPLICATION  
File No: 01-18D1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : Paul O. Sheppard et al.  
Serial No. :  
Group Art Unit :  
Examiner :  
Filed : March 2, 2004  
For : INTERFERON-LIKE PROTEIN ZCYTO21  
Date Submitted : March 2, 2004

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, DC 20231

Sir:

In compliance with the duty imposed by 37 C.F.R. §1.56, and in accordance with 37 C.F.R. §§1.97 *et seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested.

The present application is a divisional of U.S. Patent Application Serial No. 09/895,834, filed June 29, 2001.

Pursuant to the provisions of M.P.E.P. §609 and in accordance with 37 C.F.R. §1.98(d), Applicants have not included copies of the documents listed on the 1449 forms that were previously cited by or submitted to the Patent Office in a prior application identified herein.

Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 26-0290.

The Examiner is invited to contact the Undersigned at the below-listed telephone number, if there are any questions concerning this paper.

Respectfully submitted,

A handwritten signature in black ink, reading "Brian J. Walsh". The signature is written in a cursive style with a large, stylized "B" and "W".

Brian J. Walsh  
Registration No. 45,543  
(206) 442-6540

<b>FORM PTO 1449</b> (REV 2-32)	<b>U.S. DEPARTMENT OF COMMERCE</b> <b>PATENT AND TRADEMARK OFFICE</b>	File No. 01-18D1	Serial No.
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		Applicant(s): Paul O. Sheppard et al.	
		Filing Date: March 2, 2004	Group:

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)**

	A1		Adams et al., Accession No. T07139, 1993.
	A2		DOE Joint Genome Institute Stanford Human Genome Center, Accession No. AC011445, 1999.
	A3		Muzney et al., Accession No. AC0118477, 1999.
	A4		Sanger Centre Search Results, Accession No. AC011445, 2001.
	A5		University of California Santa Cruz database using Softberry, Inc. gene prediction software, Accession No. C19001084, 2001.
	A6		Scott et al., "The Pendred syndrome gene encodes a chloride-iodide transport protein," <i>Nature Genetics</i> , 21:440-443, 1999.

Examiner	Date considered
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.